
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4A4718AF224F305A471004E4EBD99.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="fbcns">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Fluids and Barriers of the CNS">
<meta name="citation_title" content="High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose">
<meta name="citation_author" content="Gillian Bonvicini">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author_institution" content="BioArctic AB, Stockholm, Sweden">
<meta name="citation_author" content="Sunitha Singh">
<meta name="citation_author_institution" content="BioArctic AB, Stockholm, Sweden">
<meta name="citation_author" content="Lisa Sandersjöö">
<meta name="citation_author_institution" content="BioArctic AB, Stockholm, Sweden">
<meta name="citation_author" content="Tiffany Dallas">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author" content="Eva Schlein">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author" content="Amelia D Dahlén">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author" content="Sara Lopes van den Broek">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author" content="Dag Sehlin">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_author" content="Ken G Andersson">
<meta name="citation_author_institution" content="BioArctic AB, Stockholm, Sweden">
<meta name="citation_author" content="Stina Syvänen">
<meta name="citation_author_institution" content="Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="22">
<meta name="citation_firstpage" content="86">
<meta name="citation_doi" content="10.1186/s12987-025-00693-2">
<meta name="citation_pmid" content="40842024">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/pdf/12987_2025_Article_693.pdf">
<meta name="description" content="Transferrin receptor (TfR)-mediated transcytosis is a well-established method for delivering biologic therapeutics and diagnostics to the brain. Although moderate affinity towards TfR is beneficial for TfR-mediated brain delivery at therapeutic ...">
<meta name="og:title" content="High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Transferrin receptor (TfR)-mediated transcytosis is a well-established method for delivering biologic therapeutics and diagnostics to the brain. Although moderate affinity towards TfR is beneficial for TfR-mediated brain delivery at therapeutic ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12369151">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12987-025-00693-2"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12987_2025_Article_693.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369151%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12369151/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12369151/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-fbcns.png" alt="Fluids and Barriers of the CNS logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Fluids and Barriers of the CNS" title="Link to Fluids and Barriers of the CNS" shape="default" href="https://fluidsbarrierscns.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Fluids Barriers CNS</button></div>. 2025 Aug 21;22:86. doi: <a href="https://doi.org/10.1186/s12987-025-00693-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12987-025-00693-2</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Fluids%20Barriers%20CNS%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fluids%20Barriers%20CNS%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Fluids%20Barriers%20CNS%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Fluids%20Barriers%20CNS%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonvicini%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Gillian Bonvicini</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Gillian Bonvicini</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">
<sup>2</sup>BioArctic AB, Stockholm, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonvicini%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gillian Bonvicini</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Singh%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Sunitha Singh</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Sunitha Singh</span></h3>
<div class="p">
<sup>2</sup>BioArctic AB, Stockholm, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Singh%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sunitha Singh</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sandersj%C3%B6%C3%B6%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Lisa Sandersjöö</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Lisa Sandersjöö</span></h3>
<div class="p">
<sup>2</sup>BioArctic AB, Stockholm, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sandersj%C3%B6%C3%B6%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lisa Sandersjöö</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dallas%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Tiffany Dallas</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Tiffany Dallas</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dallas%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tiffany Dallas</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schlein%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Eva Schlein</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Eva Schlein</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schlein%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Eva Schlein</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dahl%C3%A9n%20AD%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Amelia D Dahlén</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Amelia D Dahlén</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dahl%C3%A9n%20AD%22%5BAuthor%5D" class="usa-link"><span class="name western">Amelia D Dahlén</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lopes%20van%20den%20Broek%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Sara Lopes van den Broek</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Sara Lopes van den Broek</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lopes%20van%20den%20Broek%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sara Lopes van den Broek</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sehlin%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Dag Sehlin</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Dag Sehlin</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sehlin%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dag Sehlin</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andersson%20KG%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Ken G Andersson</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Ken G Andersson</span></h3>
<div class="p">
<sup>2</sup>BioArctic AB, Stockholm, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andersson%20KG%22%5BAuthor%5D" class="usa-link"><span class="name western">Ken G Andersson</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Syv%C3%A4nen%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Stina Syvänen</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Stina Syvänen</span></h3>
<div class="p">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Syv%C3%A4nen%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stina Syvänen</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden </div>
<div id="Aff2">
<sup>2</sup>BioArctic AB, Stockholm, Sweden </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 4; Accepted 2025 Jul 29; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12369151  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40842024/" class="usa-link">40842024</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Transferrin receptor (TfR)-mediated transcytosis is a well-established method for delivering biologic therapeutics and diagnostics to the brain. Although moderate affinity towards TfR is beneficial for TfR-mediated brain delivery at therapeutic doses, emerging evidence has indicated that high TfR affinity may be more beneficial at tracer doses. With the development of antibody-based PET radioligands for neurodegenerative diseases, such as Alzheimer’s disease, understanding the pharmacokinetics of TfR-binders at tracer dose is essential. Thus, this study aimed to evaluate the effect of TfR affinity on brain uptake at a tracer dose in both wild-type (WT) and amyloid-beta (Aβ) pathology presenting mice and to demonstrate the usability of TfR-mediated brain delivery of immunoPET diagnostic radioligands to visualize intrabrain Aβ pathology in vivo.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">Three different affinity variants of anti-mouse TfR-binding antibody 8D3, engineered by alanine point mutations, were selected. Bispecific antibodies were designed with knob-into-hole technology with one arm targeting TfR (8D3) and the other arm targeting human Aβ (bapineuzumab). Antibody affinities were measured in an in vitro cell assay. In vivo pharmacokinetic analyses of radioiodinated bispecific antibodies and bapineuzumab in brain, blood and peripheral organs were performed over 7 days post-injection in WT mice and a model of Aβ pathology (<em>App</em><sup><em>NL−G−F</em></sup>). The strongest TfR affinity bispecific antibody was also evaluated as a positron emission tomography (PET) radioligand for detecting Aβ pathology in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">The three bispecific antibodies bound to TfR with affinities of 10 nM, 20 nM and 240 nM. Independent of genotype, stronger TfR-affinity resulted in higher initial brain uptake. The two higher-affinity bispecific antibodies behaved similarly and differentiated between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice earlier than the lowest affinity variant. Finally, the 10 nM bispecific antibody was able to clearly differentiate between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice when used as a PET radioligand.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">This study supports the hypothesis that stronger TfR affinity enhances brain uptake at a tracer dose. With the more effective detection of Aβ pathology, stronger TfR affinity is a crucial design feature for future bispecific immunoPET radioligands for intrabrain targets via TfR-mediated transcytosis.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12987-025-00693-2.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Affinity, Alzheimer’s disease, Amyloid-β, Positron emission tomography (PET), Transferrin receptor (TfR)-mediated transcytosis</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Antibodies and antibody fragments make for unique therapeutic and diagnostic tools due to their innate specificity that can be directed to an extensive range of epitopes. The introduction of antibodies and protein-based drugs has considerably improved cancer treatment during the last decades [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. A similar development is presently seen for brain disorders with two monoclonal antibodies directed towards amyloid-beta (Aβ) emerging as the first disease modifying treatments for Alzheimer’s disease (AD) [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. However, as large molecules, antibodies do not cross the blood-brain barrier (BBB) efficiently [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. To overcome this obstacle, the molecular Trojan horse strategy can be applied with bispecific antibodies binding to both a central nervous system (CNS) target and a receptor on the BBB. The BBB receptor’s endogenous function is to transport essential molecules into the brain. This strategy allows the bispecific antibody to be carried across the BBB with great efficiency resulting in a several-fold increase in antibody brain concentrations.</p>
<p id="Par6">The transferrin receptor (TfR) which plays a role in iron homeostasis for the brain was first targeted in the 1990s and has become a common receptor for this strategy [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. TfR-mediated transport has proven successful in clinical phase I-III trials for delivering enzyme replacement therapies for the lysosomal storage disorder, Hunter syndrome [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. One of these treatments was approved in Japan in 2021 [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. A phase I trial for delivering Roche’s bispecific anti-Aβ/TfR antibody, Trontinemab, for AD is also on-going [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>, <a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. With the shift in the AD field for therapeutic biologics that primarily target a variety of Aβ aggregates, it would be beneficial to have companion diagnostics that detect these various aggregate forms as well. The current gold-standard positron emission tomography (PET) radioligands for detecting amyloid in the living brain are based on small molecules such as carbon-11 (<sup>11</sup>C)-labelled Pittsburgh Compound B ([<sup>11</sup>C]PiB) or other fluorine-18-labelled radioligands that bind to amyloid. These radioligands primarily bind to the dense amyloid core of Aβ plaques. Further, it should be noted that small molecule radioligands also bind to amyloid structures formed by other proteins besides Aβ, e.g. alpha-synuclein that accumulates in Parkinson’s disease or dementia with Lewy bodies [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>–<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Thus, to overcome the limitations of amyloid PET radioligands, bispecific antibody-based PET radioligands for specific detection of Aβ aggregates with the molecular Trojan horse strategy are also being developed. Antibody-based radioligands have shown in rodent Aβ models to be more sensitive than the current small molecule based amyloid radioligands, such as [<sup>11</sup>C]PiB, at detecting changes in Aβ pathology levels during disease progression or as a result of anti-Aβ treatment [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>].</p>
<p id="Par7">Over the last couple of decades, research has focused on how to best harness the TfR for brain delivery of large molecular biologics. Several factors have emerged which can influence transcytosis, including: affinity [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>–<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>], valency [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>], pH-sensitive binding [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>], and size [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Affinity has received extensive attention at therapeutic doses (5–50 mg/kg) which tend to be substantially higher than low (tracer) doses (&lt; 1 mg/kg) used for immunoPET imaging of CNS targets. It is well-accepted in the field that a moderate TfR affinity is most optimal for high brain uptake. Antibodies with too high TfR affinity are more likely to be trapped in the capillaries while antibodies with too low affinity do not interact with TfR sufficiently for transcytosis [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. However, whether this also applies in low doses is currently unclear. In fact, a limited number of studies have suggested that there is a linear relationship between TfR affinity and brain uptake at tracer doses [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Thus, opposite to the findings at therapeutic dosing, high affinity may be beneficial at low dosing.</p>
<p id="Par8">Therefore, this study aimed to further investigate the effect of TfR affinity on brain uptake at a tracer dose in wild-type (WT) mice and the <em>App</em><sup><em>NL−G−F</em></sup> mouse model of Aβ pathology. Three affinity variants of the rat-anti-mouse TfR1 (mTfR) antibody 8D3 were engineered with single alanine mutations. These TfR-affinity variants were combined with bapineuzumab (Bapi), an antibody that binds Aβ at the N-terminus, with knob-into-hole (KiH) technology to produce bispecific antibodies [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. The brain delivery and pharmacokinetics of the bispecific antibody affinity variants were studied ex vivo and in vivo by PET.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Recombinant antibody production</h3>
<section id="Sec4"><h4 class="pmc_sec_title">Design</h4>
<p id="Par9">The KiH heavy chain heterodimerization technology was used as a design to generate full-length monovalent, bispecific IgG antibodies based on anti-mTfR, 8D3, and anti-Aβ, Bapi (Fig. <a href="#Fig1" class="usa-link">1</a>A). The knob antibody was designed with Fc mutations: S354C/T366W and the hole antibody with Fc mutations: Y349C/T366S/L368A/Y407V [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. Three affinity variants of 8D3 were designed by introducing single alanine point mutations in the complementarity-determining regions (CDR) of WT 8D3: 8D3<sub>WT</sub> with no mutations, 8D3<sub>Y32A</sub> with the Y32A point mutation and 8D3<sub>Y52A</sub> with the Y52A point mutation [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. The three affinity-engineered 8D3 knob antibodies were paired with the Bapi-derived hole antibody to generate three Bapi-8D3 bispecific antibodies with varying TfR affinity (Table <a href="#Tab1" class="usa-link">1</a>). A monospecific, bivalent Bapi antibody was designed without the KiH technology as a regular IgG. LALA-PG mutations (L234A/L235A/P329G) were introduced to all produced antibodies to reduce effector function [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Genes were inserted into pcDNA3.4 plasmids by GenScript Biotech (Leiden, Netherlands) or GeneArt (ThermoFisher Scientific).</p>
<figure class="fig xbox font-sm" id="Fig1"><h5 class="obj_head">Fig. 1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369151_12987_2025_693_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/098e/12369151/7b1d8ffcfd79/12987_2025_693_Fig2_HTML.jpg" loading="lazy" id="d33e845" height="306" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Generation of bispecific antibodies with varying affinity to mTfR. (<strong>A</strong>) Schematic antibodies illustrating the KiH design of bispecific Bapi-8D3 and monospecific Bapi. (<strong>B</strong>) Mean fluorescent intensity (MFI) from the on-cell mTfR affinity assay with Bapi-8D3<sub>WT</sub>, Bapi-8D3<sub>Y32A</sub>, Bapi-8D3<sub>Y52A</sub>, Bapi. EC50 values listed below the legend. (<strong>C</strong>) ELISA analysis of bivalent (Bapi) and monovalent (Bapi-8D3<sub>Y32A</sub>) binding to Aβ with EC50 values listed below the legend</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>Hole and knob antibody pairings for the KiH antibodies with the 8D3 point mutations and CDR locations</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Bispecific antibody</th>
<th align="left" colspan="1" rowspan="1">Hole-antibody</th>
<th align="left" colspan="1" rowspan="1">Knob-antibody</th>
<th align="left" colspan="1" rowspan="1">8D3 point mutation</th>
<th align="left" colspan="1" rowspan="1">Point mutation CDR location</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Bapi-8D3</td>
<td align="left" colspan="1" rowspan="1">Bapi</td>
<td align="left" colspan="1" rowspan="1">8D3<sub>WT</sub>
</td>
<td align="left" colspan="1" rowspan="1">none</td>
<td align="left" colspan="1" rowspan="1">n.a.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bapi-8D3<sub>Y32A</sub>
</td>
<td align="left" colspan="1" rowspan="1">Bapi</td>
<td align="left" colspan="1" rowspan="1">8D3<sub>Y32A</sub>
</td>
<td align="left" colspan="1" rowspan="1">Y32A</td>
<td align="left" colspan="1" rowspan="1">HCDR1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bapi-8D3<sub>Y52A</sub>
</td>
<td align="left" colspan="1" rowspan="1">Bapi</td>
<td align="left" colspan="1" rowspan="1">8D3<sub>Y52A</sub>
</td>
<td align="left" colspan="1" rowspan="1">Y52A</td>
<td align="left" colspan="1" rowspan="1">HCDR2</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p14"><p>CDR: complementarity-determining region; HCDR1: heavy chain complementarity-determining region 1; HCDR3: heavy chain complementarity-determining region 3</p></div></div></section></section><section id="Sec5"><h4 class="pmc_sec_title">Production</h4>
<p id="Par11">Bispecific antibodies were generated with separate knob and hole antibody production followed by a disulphide exchange approach (Figure <a href="#MOESM1" class="usa-link">S1</a>). The three 8D3 knob and one Bapi hole antibodies were produced separately with the ExpiCHO Expression System following the manufacturer’s instructions (ThermoFisher Scientific, Stockholm, Sweden). Briefly, ExpiCHO-S cells (ThermoFisher Scientific) were cultured in ExpiCHO Expression medium (ThermoFisher Scientific) at 37 °C, 120 RPM orbital shaking with 80% humidity and 8% CO<sub>2</sub>. ExpiCHO-S cells (6 million viable cells/mL) were transfected with plasmids (1 µg/mL of transfection volume in a 1:1 knob or hole heavy chain plasmid to light chain plasmid ratio) mixed with ExpiFectamine CHO Reagent (ThermoFisher Scientific) and OptiPRO SFM (ThermoFisher Scientific). One day post-transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were added to the flask. Cell supernatant was harvested for purification 8 d post-transfection. Monospecific, bivalent Bapi was produced in ExpiCHO-S cells as full antibodies directly.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Purification</h4>
<p id="Par12">Knob and hole antibodies and monospecific Bapi were purified from filtered cell supernatant using a HiTrap MabSelect SuRe (Cytiva, Uppsala, Sweden) on an ÄKTA Avant system (Cytiva). A linear gradient of 0.7% acetic acid was used for elution. Following elution, knob and hole antibodies were stored at 4 °C until assembly while the buffer for monospecific Bapi was exchanged to phosphate buffered saline (PBS) with a HiPrep 26/10 Desalting column (Cytiva).</p></section><section id="Sec7"><h4 class="pmc_sec_title">Assembly into full-length bispecific antibody</h4>
<p id="Par13">KiH bispecific antibodies were assembled according to Giese and colleagues [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. Briefly, half antibodies were diluted to 13 µM, adjusted to a pH of 8-8.5 with 120 mM L-arginine, and incubated for 1 h at 35 °C. Following incubation, equal volumes of knob and hole half-antibodies were pooled together and a 200 molar excess of L-reduced glutathione was added. Antibodies incubated for 6 h at 35 °C with end-over-end mixing. The reaction was stopped by exchanging the buffer to PBS with a PD-10 desalting column (Cytiva).</p></section><section id="Sec8"><h4 class="pmc_sec_title">Polish</h4>
<p id="Par14">Assembled antibodies were further polished with ion exchange and size exclusion chromatography on an ÄKTA Purifier system (Cytiva). Samples were buffer exchanged to 20 mM TrisHCl, pH 8 with a HiPrep 26/10 desalting column and loaded onto a HiTrap Q HP ion exchange column (Cytiva). The elution buffer was a 20 mM TrisHCl and 1 M NaCl, pH 8 buffer injected from 0 to 50% over 5 column volumes. Collected samples were further purified and buffer exchanged to PBS with a HiLoad 26/600 Superdex 200 pg column (Cytiva).</p></section><section id="Sec80"><h4 class="pmc_sec_title">Quality control</h4>
<p id="Par15">Assembled KiH antibody purity was assessed with SDS-PAGE gel with both reducing and non-reducing conditions (Figure <a href="#MOESM1" class="usa-link">S2</a>). Briefly, 1 µg of antibody mixed with Bolt LDS Sample Buffer (ThermoFisher Scientific) with (reducing) or without (non-reducing) NuPAGE Sample Reducing Agent (ThermoFisher Scientific) were heated for 10 min at 90 °C, loaded on a Bolt 4–12% Bis-Tris Protein Gel (ThermoFisher Scientific) and run at 200 V for 35 min with Bolt MES SDS Running Buffer (ThermoFisher Scientific). The gel was fixed in 50% methanol and 7% acetic acid and stained with InstantBlue Coomassie Protein Stain (Abcam, Cambridge, UK).</p></section></section><section id="Sec9"><h3 class="pmc_sec_title">On-cell mTfR affinity assay</h3>
<p id="Par16">Affinity to TfR for the bispecific antibody variants was measured with the previously described in vitro cell assay with the exception that Sp2/0-Ag14 cells expressing mTfR endogenously (ATCC, Manassas, USA) were used [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. With this assay, EC50 values serve as a proxy for apparent affinity because saturation of binding sites on the cell surface is the maximum response being measured. Briefly, Sp2/0-Ag14 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Dublin, Ireland) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 1 mM HyClone Sodium Pyruvate (Cytiva), 2 mM HyClone L-Glutamine (Cytiva) and 1% HyClone Penicillin Streptomycin (Cytiva) in a humidified incubator at 37 °C with 5% CO<sub>2</sub>. The day of the affinity assay, cells were pelleted by centrifuging for 5 min at 1200 RPM, resuspended in PBS and 0.3 million viable cell/well were added to a 96 well U bottom plate. The PBS was discarded and cells were blocked with Fc receptor blocker (NB309, Innovex Biosciences Inc., Richmond, USA) for 20 min. Antibodies were added to the wells in a serial dilution from 400 nM to 6.8 pM for Bapi-8D3<sub>WT</sub>, 600 nM-10.2 pM for Bapi-8D3<sub>Y32A</sub>, and 6000 nM-102 pM for Bapi-8D3<sub>Y52A</sub> and Bapi. Concentrations were optimized to ensure an upper plateau was achieved for each antibody. Cells were incubated for 30 min at 4 °C, washed with PBS and then incubated with Alexa 488 anti-human IgG1 Fc secondary antibody (1:200 in PBS, <a href="https://www.ncbi.nlm.nih.gov/nuccore/H10120" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">H10120</a>, ThermoFisher Scientific) for 30 min at 4 °C. After incubation, cells were washed twice and finally resuspended in 200 µl of PBS. Cells were acquired using a BD FACSLyric Flow Cytometry System (BD Biosciences, San Jose, CA) and data were analysed using flowJo, version 10.8.1 (BD Biosciences). Background corrected mean fluorescent intensity (MFI) was determined by subtracting the MFI of cells incubated with only the secondary antibody from the MFI of cells incubated with both the test antibody and the secondary antibody. The background corrected MFI of two replicates was plotted against the antibody concentration.</p></section><section id="Sec10"><h3 class="pmc_sec_title">ELISA</h3>
<p id="Par17">Affinity to Aβ for the bivalent and monovalent versions of Bapi were determined using an indirect ELISA, as previously described [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Briefly, 96-well half-area plates were coated with Aβ<sub>1−42</sub> (50 nM in PBS, Innovagen, Lund, Sweden) at 4°C overnight. They were blocked with 1% BSA in PBS for 1 h. Bapi and Bapi-8D3<sub>Y32A</sub> (50 nM to 3.2 pM) were applied overnight at 4°C. The following day, plates were washed and incubated with horseradish peroxidase (HRP)-conjugated goat anti-human IgG-F(ab’)<sub>2</sub> (1:2000, #115-035-006, Jackson ImmunoResearch Laboratories, West Grove, USA) for 1 h. Following another wash, the K blue aqueous TMB substrate (Neogen Corp., Lexington, USA) was applied. The reaction was stopped with 1 M H<sub>2</sub>SO<sub>4</sub>. The resulting signal was detected with a spectrophotometer at 450 nm.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Radiochemistry</h3>
<p id="Par18">The direct iodination Chloramine-T method was used to radiolabel antibodies with iodine-125 (<sup>125</sup>I) (Table <a href="#Tab2" class="usa-link">2</a>) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. Briefly, 65.3 ± 32.8 µg of antibody was labelled with 10.3 ± 5.9 MBq of [<sup>125</sup>I]NaI stock solution (PerkinElmer Inc., Waltham, USA), by adding 5 µg of Chloramine-T (Sigma Aldrich) in a final reaction volume of 110 µl. The reaction incubated for 90 s at room temperature. Sodium metabisulfite (10 µg, Sigma Aldrich) was added to stop the reaction, bringing the final volume to 120 µL. For iodine-124 (<sup>124</sup>I) labelling, 115 µl [<sup>124</sup>I]NaI stock solution (Advanced Center Oncology Macerata, Montecosaro, Italy) was pre-incubated for 15 min with NaI at a final concentration of 10 µM, then neutralized with 0.5% acetic acid and PBS. After adding 320 µg of antibody, the reaction was initiated by the addition of 40 µg Chloramine-T (Sigma Aldrich) and then quenched with 80 µg sodium metabisulfite (Sigma Aldrich) after 120 s. Radiolabelled antibodies were diluted to 500 µL with PBS, purified using a NAP-5 size exclusion column (Cytiva) to remove any free iodine and eluted in PBS. Indirect ELISAs were performed as quality control to ensure that the radiolabelled antibodies had retained their binding affinity to mTfR (1 µg/ml for Bapi-8D3<sub>WT</sub> and Bapi-8D3<sub>Y32A</sub>; 10 µg/ml for Bapi-8D3<sub>Y52A</sub>) and Aβ (50 nM) (Figure <a href="#MOESM1" class="usa-link">S3</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Radiochemical reaction yield and specific activity of radioligands</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Radioligand</th>
<th align="left" colspan="1" rowspan="1">Radiochemical yield (%)</th>
<th align="left" colspan="1" rowspan="1">Molar activity (MBq/nmol)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub>
</td>
<td align="center" colspan="1" rowspan="1">83.4</td>
<td align="center" colspan="1" rowspan="1">16.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>
</td>
<td align="center" colspan="1" rowspan="1">78.0 ± 6.4</td>
<td align="center" colspan="1" rowspan="1">18.4 ± 3.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>
</td>
<td align="center" colspan="1" rowspan="1">88.7 ± 1.6</td>
<td align="center" colspan="1" rowspan="1">23.3 ± 1.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>
</td>
<td align="center" colspan="1" rowspan="1">81.2 ± 7.7</td>
<td align="center" colspan="1" rowspan="1">19.6 ± 6.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]IBapi</td>
<td align="center" colspan="1" rowspan="1">85.7 ± 5.2</td>
<td align="center" colspan="1" rowspan="1">23.8 ± 1.9</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec12"><h3 class="pmc_sec_title">Mice</h3>
<p id="Par20">Ex vivo biodistribution studies and PET imaging were performed on 12–18 month old WT C57BL/6 mice (<em>n</em> = 53) and <em>App</em><sup><em>NL−G−F</em></sup> mice (<em>n</em> = 53). The <em>App</em><sup><em>NL−G−F</em></sup> model is a knock-in model which expresses mouse amyloid precursor protein (APP) with a humanized Aβ sequence harbouring the Swedish (<em>KM670/671NL</em>), Arctic (<em>E693G</em>), and Iberian (<em>I716F</em>) mutations. This model displays aggressive amyloidosis with Aβ plaque pathology beginning around 3 months and consisting mainly of Aβ<sub>1−42</sub> [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. Both males and females were included. The number of mice for each experiment and the dose of each antibody are given in Table <a href="#MOESM1" class="usa-link">S1</a>. All procedures involving mice were approved by the Uppsala County Animal Ethics board (5.8.18–20401/2020) and carried out in accordance with the Swedish Animal Welfare Agency regulations and the European Communities Council Directive of 22 September 2010 (2010/63/EU). Mice were housed in an approved animal facility at Uppsala University with free access to food and water.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Pharmacokinetics and ex vivo biodistribution</h3>
<p id="Par21">WT or <em>App</em><sup><em>NL−G−F</em></sup> mice under mild isoflurane sedation (Baxter Medical AB, Kista, Sweden) received a tracer dose (0.21 ± 0.02 mg/kg, 1.00 ± 0.20 MBq) of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>, or [<sup>125</sup>I]I-Bapi injected intravenously. Blood (8 µL) was sampled from the tail vein 1, 2, 4, 6, 24, 48, 72 and 168 h post-injection.</p>
<p id="Par22">Prior to euthanasia, mice were anaesthetized with isoflurane and a terminal blood sample was collected from the heart. Half of the terminal blood sample was separated into plasma and blood cell pellet by centrifugation at 10,000 x g for 5 min. Mice were euthanized at 4, 24, 72 and 168 h post-injection via transcardial perfusion with 40 mL of 0.9% NaCl for 2.5 min. Immediately after, the left cortex was collected for capillary depletion and the right hemisphere, left midbrain and left cerebellum were frozen on dry ice. Lung, heart, liver, pancreas, spleen, kidney, femoral muscle, femoral bone, skull and thyroid were harvested and a urine sample was collected. Radioactivity in all samples was measured by γ-counting (2480 Wizard™, PerkinElmer). Antibody concentrations were expressed as percent of the injected dose of activity per gram tissue:</p>
<p id="Par23">%ID/g = measured radioactivity per gram tissue / total injected dose of radioactivity x 100.</p></section><section id="Sec14"><h3 class="pmc_sec_title">Capillary depletion</h3>
<p id="Par24">Perfused left cortices underwent capillary depletion immediately after perfusion as previously described [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Briefly, cortices were homogenized with 6 strokes in an ice-cold Dounce homogeniser in 0.4 mL cold physiological buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl<sub>2</sub>, 1 mM MgSO<sub>4</sub>, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM D-glucose, pH 7.4) before adding 0.8 ml of 30% Ficoll 400 (Sigma Aldrich) and homogenizing with 2 more strokes. Homogenates were centrifuged at 3900 g for 30 min at 4 °C. The two fractions, a capillary enriched pellet and a parenchymal supernatant, were separated, and the radioactivity in each fraction was measured by γ-counting (PerkinElmer).</p></section><section id="Sec15"><h3 class="pmc_sec_title">Ex vivo autoradiography</h3>
<p id="Par25">One mouse from each time point was randomly selected and the right hemisphere from these mice were cryosectioned (CM1850, Leica Biosystems, Nussloch, Germany) into 20 μm sagittal sections. Two sections per mouse were exposed to a phosphor imaging plate (MS, MultiSensitive, PerkinElmer) for 10 days. Plates were scanned in a Typhoon phosphor imager (Cytiva). The resulting digital images were decay corrected to the day of injection, normalized to the injected dose and converted to a false colour scale (Royal) in ImageJ.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Aβ immunohistochemistry</h3>
<p id="Par26">Immunohistochemistry was performed on sections from mice euthanized at 72 h post-injection. Brain sections were fixed in 4% paraformaldehyde and washed in PBS. Sections were boiled in 25 mM citrate buffer (pH 7.3) for 10 s and left to cool to room temperature for 20 min before being treated with 70% formic acid (FA) for 5 min. Following the formic acid treatment, sections were rinsed in milliQ water and washed in PBS. Endogenous peroxidase was blocked with 20 min exposure to 3% hydrogen peroxide. Since a mouse primary antibody was used for staining mouse tissue, the M.O.M. Mouse Ig Blocking Reagent (Vector Laboratories Inc., California, USA) was used according to the manufacturer’s instructions. Sections were permeabilized with 0.4% triton X-100 in PBS for 5 min. The primary antibody, 3D6 (murine version of Bapi, produced in-house [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]), was diluted to 10 µg/ml in 0.1% Tween-20 in PBS supplemented with MOM mouse diluent (Vector Laboratories Inc.) and added to the sections overnight at 4 °C. The next day, sections were washed in PBS and the secondary goat-anti-mouse-biotin antibody (1:250 in PBS, BA-9200-15, Vector Laboratories Inc.) was added for 45 min at room temperature. Sections were washed before incubating with streptavidin-HRP (1:500 in PBS; Mabtech AB, Nacka Strand, Sweden) for 45 min. After another wash, the peroxidase substrate from the NovaRED Substrate Kit (Vector Laboratories Inc.) was applied for 3 min following the manufacturer’s instructions. Sections were washed again, counterstained with haematoxylin and rinsed in tap water for 5 min. Then sections were dehydrated in increasing concentrations of ethanol and xylene before mounting with Pertex mounting medium (Histolab, Stockholm, Sweden). Brightfield images were acquired with a Zeiss Observer Z1 microscope (Carl Zeiss Imaging GmBH, Jena, Germany) and processed using ZEN 3.7 software (Carl Zeiss Imaging GmBH).</p></section><section id="Sec17"><h3 class="pmc_sec_title">PET imaging</h3>
<p id="Par27">For PET imaging, WT or <em>App</em><sup><em>NL−G−F</em></sup> mice were intravenously administered with [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> (1.15 ± 0.01 mg/kg, 4.19 ± 0.50 MBq) under mild isoflurane sedation (Baxter). At 72 h post-administration, mice underwent a 90 min PET scan (Mediso NanoPET/MR, Mediso Medical Imaging System, Hungary) followed by a 5 min CT (Mediso NanoSPECT/CT, Mediso Medical Imaging System). Anaesthesia was maintained during scanning with 3.5–4.0% sevoflurane in a 0.5 L/min flow of 50% oxygen and 50% medical air. After scanning, the mice were perfused, the brain was isolated and the radioactivity in the brain was measured by γ-counting (PerkinElmer) according to the same procedure as described above for ex vivo studies. The PET data was reconstructed on a 160 × 160 × 128 grid with 0.5 × 0.5 × 0.6 mm<sup>3</sup> voxels using 3-dimensional ordered-subsets expectation maximisation (20 iterations). The CT raw files were reconstructed using filtered back-projection. Processing of the PET and CT images was performed with Amide, version 1.0.4 [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. The CT scans were manually aligned with a T2-weighted, MRI-based mouse brain atlas containing outlined regions of interest (ROIs) [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. The PET images were subsequently aligned with the CT image containing the brain atlas ROIs. The average activity in each ROI was converted to %ID/g brain, assuming that one cm<sup>3</sup> corresponded to one gram of brain tissue.</p></section><section id="Sec18"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="Par28">GraphPad Prism 9.4.1 was used for statistical analyses. The EC50 values for the on-cell affinity assay and ELISA were calculated from agonist concentration vs. response curves with variable slope (four parameters). Results are reported as mean ± standard deviation, except for the area under the concentration curve (AUC) graphs which are the mean ± standard error. The whole blood half-life was calculated using a two-phase decay model and Y0 was set to 50% as previously described [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. The half-life for each antibody and mouse genotype was expressed as the mean ± standard deviation based on mice that were euthanized at 3 and 7 days post-injection. A two-way ANOVA with Šídák’s multiple comparisons test was performed to determine at which time point the brain concentration of each antibody significantly differed between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice in ex vivo studies, and to assess regional concentration differences between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice in the PET studies. An unpaired t-test was used to compare ex vivo measured whole brain concentrations between WT and <em>App</em><sup><em>NL−G−F</em></sup> in PET-scanned mice. Differences between brain and blood pharmacokinetic AUCs were assessed with Brown-Forsythe and the Welch ANOVA tests with Dunnett’s T3 multiple comparisons test. All other data were not subjected to statistical testing, and any reported differences should be interpreted as observed trends rather than statistically confirmed effects.</p></section></section><section id="Sec19"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec20"><h3 class="pmc_sec_title">Alanine point mutations yielded three mTfR affinity variants</h3>
<p id="Par29">Bispecific Bapi-8D3 antibodies and Bapi were produced with the KiH design (Fig. <a href="#Fig1" class="usa-link">1</a>A, <a href="#MOESM1" class="usa-link">S2</a>). In an on-cell mTfR affinity assay, the EC50 of Bapi-8D3<sub>Y32A</sub> and Bapi-8D3<sub>Y52A</sub> was 2-fold and 24-fold higher, respectively, than the EC50 of Bapi-8D3<sub>WT</sub> (Fig. <a href="#Fig1" class="usa-link">1</a>B, Table <a href="#MOESM1" class="usa-link">S2</a>). Bapi also bound to Aβ with a sub-nanomolar EC50 in both the bivalent (Bapi) and monovalent (Bapi-8D3<sub>Y32A</sub>) formats (Fig. <a href="#Fig1" class="usa-link">1</a>C).</p></section><section id="Sec21"><h3 class="pmc_sec_title">Bispecific antibodies with stronger TfR-affinity had higher brain uptake at a tracer dose</h3>
<p id="Par31">To assess how antibodies with a TfR-binding modality with different affinities behave in vivo, each antibody was radiolabelled with <sup>125</sup>I and injected into mice at a tracer dose of 0.2 mg/kg. The brain concentrations of the stronger TfR binders, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, were similar 4 h post-injection (Fig. <a href="#Fig2" class="usa-link">2</a>A), 6- to 13-fold higher than [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>, and 16- to 27-fold higher than [<sup>125</sup>I]I-Bapi. The concentration in the brain 4 h post-injection was similar between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice for each antibody. Over time, the concentration of injected antibody in the brain decreased in WT mice and increased in <em>App</em><sup><em>NL−G−F</em></sup> mice. These trends occurred in both the cerebrum and cerebellum (Figure S4). The first time point in which the brain concentration of antibody was significantly different between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice was 24 h post-injection for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> (<em>p</em> &lt; 0.001) and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> (<em>p</em> &lt; 0.001) and 72 h for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> (<em>p</em> &lt; 0.01) and [<sup>125</sup>I]I-Bapi (<em>p</em> &lt; 0.01, Fig. <a href="#Fig2" class="usa-link">2</a>A). The blood kinetics were comparable between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice for each antibody and showed a trend that stronger affinity to mTfR resulted in quicker blood elimination (Fig. <a href="#Fig2" class="usa-link">2</a>B; Table <a href="#Tab3" class="usa-link">3</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369151_12987_2025_693_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/098e/12369151/6de167d486f3/12987_2025_693_Fig3_HTML.jpg" loading="lazy" id="d33e1403" height="719" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Ex vivo biodistribution of three bispecific affinity variants and Bapi in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice over 168 h post-injection. (<strong>A</strong>) Brain concentrations (%ID/g) of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice 4, 24, 72, and 168 h post-injection. The first time when the concentration in <em>App</em><sup><em>NL−G−F</em></sup> mice is significantly higher than the concentration in WT mice is indicated by a solid arrow for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> and a dashed arrow for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi. (<strong>B</strong>) Whole blood pharmacokinetics (%ID/g of blood) over 168 h post-injection. (<strong>C</strong>) Brain-to-blood ratio in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice 4, 24, 72, and 168 h post-administration. AUC from the brain (AUC<sub>brain</sub>, <strong>D</strong>) and blood (AUC<sub>blood</sub>, <strong>E</strong>) pharmacokinetic curves of each antibody in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice (* <em>p</em> ≤ 0.05, ** <em>p</em> ≤ 0.01, *** <em>p</em> ≤ 0.001, **** <em>p</em> &lt; 0.0001). (<strong>F</strong>) The ratio of AUC<sub>brain</sub>/AUC<sub>blood</sub> for each antibody in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice. Concentrations (%ID) in the capillary enriched pellet (<strong>G</strong>) and parenchymal supernatant (<strong>H</strong>) from capillary depletion of cortices at 4, 24, 72 and 168 h post-administration. (<strong>I</strong>) Percent in plasma fraction of total blood in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice 4, 24, 72, and 168 h post-administration</p></figcaption></figure><section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Elimination half-life (h) in whole blood</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">WT</th>
<th align="left" colspan="1" rowspan="1">App<sup>NL−G−F</sup>
</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>
</td>
<td align="center" colspan="1" rowspan="1">18.0 ± 5.5</td>
<td align="center" colspan="1" rowspan="1">16.7 ± 5.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>
</td>
<td align="center" colspan="1" rowspan="1">15.2 ± 2.2</td>
<td align="center" colspan="1" rowspan="1">15.3 ± 2.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>
</td>
<td align="center" colspan="1" rowspan="1">34.4 ± 19.8</td>
<td align="center" colspan="1" rowspan="1">21.7 ± 10.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">[<sup>125</sup>I]I-Bapi</td>
<td align="center" colspan="1" rowspan="1">26.0 ± 9.7</td>
<td align="center" colspan="1" rowspan="1">22.5 ± 8.8</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p41"><p>Data presented as mean ± standard deviation</p></div></div></section><p id="Par32">The brain-to-blood ratio for each antibody was similar between <em>App</em><sup><em>NL−G−F</em></sup> and WT mice 4 h post-injection (Fig. <a href="#Fig2" class="usa-link">2</a>C). In WT mice, the brain-to-blood ratio peaked at 24 h for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, while it stayed constantly low for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi over the 168 h post-injection study period. The brain-to-blood ratio in <em>App</em><sup><em>NL−G−F</em></sup> mice continued to increase until the final time point for each antibody. At 168 h post-injection, the brain-to-blood ratio for the bispecific antibody with the highest TfR affinity, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>, was 2-fold higher, 31-fold higher and 150-fold higher than the ratios observed for [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>, and [<sup>125</sup>I]I-Bapi, respectively.</p>
<p id="Par34">The ranking of AUC<sub>brain</sub> for the antibodies was the same in both WT and <em>App</em><sup><em>NL−G−F</em></sup> mice (Fig. <a href="#Fig2" class="usa-link">2</a>D). The AUC<sub>brain</sub> for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and for [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> did not significantly differ from each other (WT: <em>p</em> &gt; 0.999; <em>App</em><sup><em>NL−G−F</em></sup>: <em>p</em> = 0.654). The AUC<sub>brain</sub> for both [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> were significantly higher than the AUC<sub>brain</sub> for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> (WT: 4-fold, <em>p</em> &lt; 0.05; <em>App</em><sup><em>NL−G−F</em></sup>: 8 to 9-fold, <em>p</em> &lt; 0.001). The AUC<sub>brain</sub> for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> was significantly higher than the AUC<sub>brain</sub> for [<sup>125</sup>I]I-Bapi (WT: 4-fold, <em>p</em> &lt; 0.05; <em>App</em><sup><em>NL−G−F</em></sup>: 4-fold, <em>p</em> &lt; 0.05).</p>
<p id="Par35">Overall, the AUC<sub>blood</sub> for each antibody did not differ between WT or <em>App</em><sup><em>NL−G−F</em></sup> mice (Fig. <a href="#Fig2" class="usa-link">2</a>E). The statistical analysis of the AUC<sub>blood</sub> supported the trend that stronger affinity to mTfR resulted in quicker blood elimination.</p>
<p id="Par36">The ratio of AUC<sub>brain</sub> and AUC<sub>blood</sub> (AUC<sub>brain</sub>/AUC<sub>blood</sub>) was always higher in <em>App</em><sup><em>NL−G−F</em></sup> mice than in WT mice (11-fold for both [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>; 7-fold for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>; 4-fold for [<sup>125</sup>I]I-Bapi; Fig. <a href="#Fig2" class="usa-link">2</a>F). Independent of genotype, the AUC<sub>brain</sub>/AUC<sub>blood</sub> ratio for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> was similar to the ratio for [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>. Both of these ratios were 8- to 15-fold higher than the ratio for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and 21- to 65-fold higher than [<sup>125</sup>I]I-Bapi.</p>
<p id="Par37">Capillary depletion was performed to further investigate the fraction of radiolabelled antibodies that reached the brain parenchyma and the fraction that was retained in the capillaries, likely as a consequence of binding to TfR expressed by the endothelial cells of the BBB (Fig. <a href="#Fig2" class="usa-link">2</a>G, H). In the capillary enriched pellet, there were low levels of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> at every time point and undetectable levels of low TfR-affinity [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and non-TfR-binding [<sup>125</sup>I]I-Bapi (Fig. <a href="#Fig2" class="usa-link">2</a>G). The antibody concentrations in the parenchymal fraction reflected the total brain pharmacokinetics well (Fig. <a href="#Fig2" class="usa-link">2</a>H). Overall, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> parenchymal concentrations were higher than the concentration of [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> while the parenchymal concentration of [<sup>125</sup>I]I-Bapi was below the detection limits. At 4 h post-injection, there were similar parenchymal levels of each antibody in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice. Over the 168 h post-injection, the parenchymal concentrations of each antibody then decreased in WT mice and increased in <em>App</em><sup><em>NL−G−F</em></sup> mice. Even the parenchymal concentration of [<sup>125</sup>I]I-Bapi was detectable in <em>App</em><sup><em>NL−G−F</em></sup> mice at 168 h post-injection.</p>
<p id="Par39">At 4 h post-injection in both WT and <em>App</em><sup><em>NL−G−F</em></sup> mice, the percentage of radioactivity in plasma (relative to total blood) for the stronger TfR binders, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, tended to be lower than for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi (Fig. <a href="#Fig2" class="usa-link">2</a>I). The percentage of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> in plasma increased over time so that at 168 h post-injection, the percentage in plasma was similar for all antibodies in both genotypes.</p>
<p id="Par40">Peripherally, the antibodies behaved similarly in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice (Figure S5). All three radiolabelled bispecific TfR-binding antibodies had higher concentrations in the spleen than [<sup>125</sup>I]I-Bapi, the control without a TfR-binding domain, at 4 h post-injection. The level in the spleen also reflected the bispecific antibody affinity to TfR such that the concentration in the spleen of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> was higher than [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> which was higher than [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>. The concentrations of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> were also higher than the concentrations of [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi in both the bone and skull at 4 h post-injection. Over time, the concentration in peripheral organs decreased for all antibodies in both WT and <em>App</em><sup><em>NL−G−F</em></sup> mice.</p></section><section id="Sec22"><h3 class="pmc_sec_title">Stronger TfR-affinity binders had a more even distribution in the <em>App</em><sup><em>NL-G-F</em></sup> brain that matched Aβ pathology</h3>
<p id="Par42">Autoradiography performed on sections from mice injected with each antibody and sacrificed at the different time points illustrated the trends from the ex vivo biodistribution (Fig. <a href="#Fig3" class="usa-link">3</a>). The radioactive signal increased in <em>App</em><sup><em>NL−G−F</em></sup> sections and decreased in WT sections over the 168 h post-injection. There was higher overall signal for the stronger TfR binders, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, than for [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369151_12987_2025_693_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/098e/12369151/dc69cd672be4/12987_2025_693_Fig4_HTML.jpg" loading="lazy" id="d33e1536" height="438" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Ex vivo autoradiography of three bispecific affinity variants and Bapi in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice over 168 h post-injection. Autoradiography in sagittal sections from WT and <em>App</em><sup><em>NL−G−F</em></sup> mice injected with [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi at 4, 24, 72 and 168 h post-injection. The intensity for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> are scaled differently than [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi</p></figcaption></figure><p id="Par43">The autoradiography further illustrated the distribution of radiolabelled antibody within the brain. [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> distributed evenly throughout the brain while [<sup>125</sup>I]I-Bapi localized in hotspots. The distribution of [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> was a mix of both distribution types. It had a uniform (although low) signal throughout the brain and the hotspots near the ventricles (Figs. <a href="#Fig3" class="usa-link">3</a> and <a href="#Fig4" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369151_12987_2025_693_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/098e/12369151/2438016f523c/12987_2025_693_Fig5_HTML.jpg" loading="lazy" id="d33e1641" height="205" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>More even antibody distribution with higher affinity to mTfR. Ex vivo autoradiography and Aβ immunohistochemistry (IHC) in sections from <em>App</em><sup><em>NL−G−F</em></sup> mice 72 h post-injection of [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi. The intensity for [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> are scaled differently than [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> and [<sup>125</sup>I]I-Bapi</p></figcaption></figure><p id="Par45">Immunohistochemical staining of Aβ confirmed that there was extensive pathology throughout the brains of <em>App</em><sup><em>NL−G−F</em></sup> mice at this age, including in the hippocampus, cortex, and cerebellum (Fig. <a href="#Fig4" class="usa-link">4</a>). The autoradiography signal from the bispecific antibodies 72 h post-injection co-localized well with pathology throughout the entire brain section. One radioactive hotspot in the sections from mice injected with [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub> or [<sup>125</sup>I]I-Bapi co-localized with the pathology in the hippocampus but overall, the radioactive hotspots did not properly reflect Aβ pathology throughout the brain section.</p></section><section id="Sec23"><h3 class="pmc_sec_title">PET-imaging differentiates between <em>App</em><sup><em>NL-G-F</em></sup> and WT mice</h3>
<p id="Par46">PET images acquired 72 h post-administration of [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> showed a significantly higher signal in <em>App</em><sup>NL−G−F</sup> mice compared to WT mice (Fig. <a href="#Fig5" class="usa-link">5</a>A). Consistent with previous ex vivo gamma counting results obtained with the <sup>125</sup>I-labelled version, image-based quantification indicated [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> brain concentrations of around 2%ID/g brain in most brain regions of <em>App</em><sup>NL−G−F</sup> mice (Fig. <a href="#Fig5" class="usa-link">5</a>B). This was further confirmed by ex vivo gamma counting of isolated brains post-PET (Fig. <a href="#Fig5" class="usa-link">5</a>C). In WT mice, brain concentrations of [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> were 0.3%ID/g brain based on PET quantification in the living brain, and 0.1%ID/g brain based on ex vivo gamma counting of perfused brains after PET scanning.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369151_12987_2025_693_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/098e/12369151/d04b4c770399/12987_2025_693_Fig6_HTML.jpg" loading="lazy" id="d33e1760" height="434" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PET imaging reveals more intense signal in <em>App</em><sup><em>NL−G−F</em></sup> _mice compared to WT. (<strong>A</strong>) Sagittal PET/CT images acquired at 72 h post administration of [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub>. The antibody was retained more in the brain of the <em>App</em><sup><em>NL−G−F</em></sup> mice with Aβ pathology than in WT mice without pathology demonstrating that it could be used as a diagnostic tool to visualize the regional distribution of Aβ pathology in the living brain. (<strong>B</strong>) Quantification of [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> brain concentrations based on PET images in different brain regions expressed as %ID/g brain. (<strong>C</strong>) Brain concentrations of [<sup>124</sup>I]I-Bapi-8D3<sub>WT</sub> based on gamma counting and expressed as %ID/g brain. (* <em>p</em> ≤ 0.05, ** <em>p</em> ≤ 0.01, *** <em>p</em> ≤ 0.001, **** <em>p</em> &lt; 0.0001)</p></figcaption></figure></section></section><section id="Sec24"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par48">Three Bapi-8D3 bispecific antibodies with different affinities to mTfR were used to study how TfR affinity influences brain uptake in WT and <em>App</em><sup><em>NL−G−F</em></sup> mice at a tracer dose. The effects of affinity on transcytosis have been thoroughly studied at therapeutic doses but few studies have explored the effects at lower doses [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>–<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Understanding TfR-mediated transcytosis at tracer doses is becoming more relevant with the development of bispecific antibody-based PET radioligands for diagnosing CNS diseases [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>–<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. At a tracer dose of 0.2 mg/kg, higher affinity to TfR resulted in higher brain uptake than lower TfR affinity. Despite the 2-fold difference in affinity in vitro, the two stronger TfR-binding bispecific antibodies, [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub>, had similar in vivo brain pharmacokinetics. Their initial brain uptake (%ID/g brain) and overall brain exposure (AUC<sub>brain</sub>) were higher than the weaker bispecific antibody, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>; which in turn had higher initial brain uptake and overall brain exposure than the control [<sup>125</sup>I]I-Bapi without TfR affinity. The capillary depletion further confirmed that successful transcytosis of antibodies into the brain had occurred and that the differences in brain uptake were primarily driven by changes in parenchymal antibody concentrations. This trend supports the proposed hypothesis in literature that the effects of TfR affinity on brain transcytosis are dose-dependent, i.e. that higher affinity results in increased brain delivery at low doses [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>].</p>
<p id="Par49">The similar pharmacokinetic profiles between [<sup>125</sup>I]I-Bapi-8D3<sub>WT</sub> and [<sup>125</sup>I]I-Bapi-8D3<sub>Y32A</sub> were also consistent with previous findings in literature. Yu and colleagues tested four antibodies with varying affinities against TfR: 1.7 nM, 6.9 nM, 65 nM and 111 nM [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The antibody with 1.7 nM affinity had the highest brain concentrations 4 h post-injection and the 111 nM affinity antibody had the lowest. In the middle, the 6.9 and 65 nM affinity antibodies followed the same brain concentration profiles over 24 h post-injection. The affinities of the two stronger TfR-binding bispecific antibodies developed in the present study were also within this affinity range. Therefore, while there appears to be a linear relationship between affinity and transcytosis efficiency at tracer doses, there seems to be an affinity range between approximately 5 and 65 nM where this effect plateaus. One limitation of this study was the affinity range of the three 8D3 variants. Since the strongest affinity variant was the WT form of 8D3, it was not possible to test affinities stronger than 10 nM with the monovalent design. An 8D3 variant with nanomolar or sub-nanomolar affinity and a variant with an affinity around 100 nM (i.e. between Bapi-8D3<sub>Y32A</sub> and Bapi-8D3<sub>Y52A</sub>) would be beneficial to further investigate the effects of affinity on TfR-binding bispecific antibody pharmacokinetics at a tracer dose.</p>
<p id="Par50">The binding strength to TfR impacted the distribution of the four antibodies in blood and to peripheral organs in both WT and <em>App</em><sup><em>NL−G−F</em></sup> mice such that there was quicker elimination from blood and higher peripheral uptake with stronger binding. In fact, the weakest TfR-binding bispecific antibody, [<sup>125</sup>I]I-Bapi-8D3<sub>Y52A</sub>, had a similar blood exposure (AUC<sub>blood</sub>) to [<sup>125</sup>I]I-Bapi, the control antibody that had no binding to TfR. This relationship aligned well with previous studies [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Peripheral tissue with high TfR expression levels such as the spleen, bone and skull also showed a direct relationship between affinity and tissue concentrations, especially 4 h post-injection. Clearance from blood is mediated by binding to TfR at the BBB and on peripheral organs and thus, a stronger affinity to TfR increases the availability of the antibody to interact with tissue outside the blood.</p>
<p id="Par51">Size and valency have also been suggested to influence transcytosis efficiency [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>–<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Therefore, the KiH design used here offers two advantages. Firstly, it ensured uniform size amongst all four antibodies. Another advantage is that this design allowed for monovalent binding to TfR. Monovalent binding is considered optimal when hijacking the TfR for BBB transportation because multivalent binding has been shown to cause TfR clustering and lysosomal degradation of both TfR and the antibody [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>].</p>
<p id="Par52">Stronger TfR affinity also led to more sensitive detection of Aβ pathology. For each antibody, the total brain and parenchymal concentrations 4 h post-injection were the same between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice. The concentrations in both total brain and parenchyma proceeded to increase in <em>App</em><sup><em>NL−G−F</em></sup> mice and decrease in WT mice over the following 164 h. The discrepancy in pharmacokinetic profiles between genotypes is attributable to the presence of extracellular Aβ deposits in <em>App</em><sup><em>NL−G−F</em></sup> mice. Upon entering the brain parenchyma, antibodies targeting the TfR also bind to neuronal TfR, leading to internalization and subsequent intracellular catabolism. This process is more pronounced in WT mice, which lack Aβ deposits, allowing for greater antibody uptake and degradation. Because iodine-125 is a non-residualizing radionuclide, it is released from the cells following catabolism, resulting in a gradual decline in the radioactive signal over time, as observed in the WT mice in this study. This phenomenon has been clearly demonstrated in previous dual labelling studies [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. TfR-binding antibodies labelled with a residualizing radionuclide, such as radiometals (e.g., copper-64, zirconium-89, or indium-111), and a non-residualizing radionuclide, such as iodine-125, have shown that residualizing radionuclides accumulate in neurons over time, while non-residualizing radionuclides are gradually excreted from the tissue. However, a bispecific antibody with higher affinity for its intraparenchymal target than for TfR will preferentially bind to the parenchymal target upon crossing the BBB. This targeted accumulation limits internalization and degradation within neurons. Similar brain concentration profiles have been observed with bispecific antibodies targeting TfR and other intraparenchymal proteins, such as myelin oligodendrocyte glycoprotein [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>].</p>
<p id="Par53">Despite similarly shaped brain concentration profiles, the two bispecific antibodies with stronger TfR affinity could differentiate between genotypes earlier than the weakest bispecific antibody and control antibody. Stronger TfR affinity also resulted in better target engagement with Aβ pathology as seen with the autoradiography and immunohistochemical stainings. The control antibody showed hotspots characteristic of antibodies without a TfR-binding modality [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. The stronger the affinity to TfR, the more evenly distributed the autoradiography signal was and the better the autoradiography signal reflected the immunohistochemically stained Aβ pathology. Altogether, the ex vivo results suggested that low dosing, combined with high affinity for TfR, promotes rapid and efficient accumulation of the bispecific antibody at the target site. At the same time, this approach contributes to the decline in radioiodine signal in the brains of WT mice, which might otherwise be masked by ongoing brain uptake at higher doses or with lower-affinity constructs. This strategy therefore enhances the contrast between the presence and absence of an extracellular antigen such as parenchymal Aβ. Moreover, it is likely to increase the sensitivity of antibody-based PET radioligands for detecting early Aβ pathology, and strongly supports the use of this approach in molecular imaging applications, particularly when the CNS target is extracellular.</p>
<p id="Par54">Consistent with this reasoning, in vivo imaging using the highest-affinity TfR-binding bispecific antibody as an immunoPET radioligand achieved unparalleled visualization of Aβ pathology in the brains of <em>App</em><sup>NL−G−F</sup> mice. In contrast, WT mice lacking Aβ showed low radioligand retention. Notably, in vivo PET quantification of radioligand concentrations in the brains of WT mice indicated higher levels compared to those measured ex vivo by gamma counting of perfused brains. This discrepancy arises because the living brain contains approximately 5% blood, and the radioligand in the brain’s blood volume enhances the PET signal in WT mice. This is a crucial consideration when selecting compounds for immunoPET applications as rapid clearance from the blood is likely to improve the distinction between brains with Aβ pathology and those without. This is another important difference from therapeutic constructs, where longer circulation times are typically preferable. Furthermore, the use of different radionuclides may lead to different imaging results [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>] and thus, brain delivery of an immunoPET radioligand with different radiolabels may benefit from optimizing the brain uptake kinetics via TfR affinity optimization.</p>
<p id="Par55">Previous studies of bispecific antibodies with maintained effector functions have displayed the ability to differentiate between WT mice and mice that express an intrabrain target such as Aβ. Despite this, these bispecific antibodies have consistently shown decreasing target bound concentrations in the brain over time after a tracer dose injection [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>, <a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. In the present study, antibody concentrations continued to increase in the brains of mice with Aβ brain pathology during the full 168 h post-injection study period. The loss of effector function that was achieved by the insertion of the LALA-PG mutations and the efficient transcytosis due to monovalent TfR-binding likely contributed to the observed absence of net-elimination. In line with this, the brain concentrations of bispecific antibodies with monovalent TfR-binding and reduced effector function (LALA/G237A or LALA/K322A mutations) or no Fc at all (a di-scFv design) decreased in WT mice while they initially increased or plateaued in transgenic Aβ mouse models over time after tracer dose injections [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>, <a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. In addition, elimination of effector function is also a beneficial design trait for bispecific antibody-based PET ligands to avoid both central and peripheral immune responses.</p>
<p id="Par56">In conclusion, the use of KiH-format bispecific anti-Aβ/mTfR antibodies with varying TfR affinities supports the hypothesis that higher TfR affinity leads to increased brain uptake at tracer doses. Furthermore, bispecific antibodies with stronger TfR affinity differentiated between WT and <em>App</em><sup><em>NL−G−F</em></sup> mice earlier and visualized Aβ pathology more distinctively than the bispecific antibody with weaker or no TfR affinity. Loss of antibody effector function potentially reduced the elimination from brain. ImmunoPET imaging using a low dose of the bispecific antibody with the highest TfR affinity showed intense signals in <em>App</em><sup><em>NL−G−F</em></sup> mice and a clear differentiation from WT mice. Overall, stronger affinity to TfR is a critical feature when designing future bispecific immunoPET radioligands for CNS targets that will leverage TfR-mediated transcytosis for crossing the BBB.</p></section><section id="Sec160"><h2 class="pmc_sec_title">Electronic supplementary material</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12369151/bin/12987_2025_693_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (1.3MB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank Josefine Karlsson for protein production support and Monique Bonvicini for experimental support. The molecular imaging work in this study was performed at the Preclinical PET-MRI Platform, a research infrastructure at Uppsala University, Sweden. The schematic illustrations were made in part using Biorender.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>[<sup>11</sup>C]PiB</dt>
<dd><p id="Par60">[<sup>11</sup>C]Pittsburgh Compound B</p></dd>
<dt>
<sup>124</sup>I</dt>
<dd><p id="Par61">iodine-124</p></dd>
<dt>
<sup>125</sup>I</dt>
<dd><p id="Par62">iodine-125</p></dd>
<dt>Aβ</dt>
<dd><p id="Par63">amyloid-beta</p></dd>
<dt>AD</dt>
<dd><p id="Par64">Alzheimer’s disease</p></dd>
<dt>AUC</dt>
<dd><p id="Par65">area under the curve</p></dd>
<dt>AUC<sub>blood</sub>
</dt>
<dd><p id="Par66">AUC for the blood pharmacokinetics</p></dd>
<dt>AUC<sub>brain</sub>
</dt>
<dd><p id="Par67">AUC for the brain pharmacokinetics</p></dd>
<dt>AUC<sub>brain</sub>/AUC<sub>blood</sub>
</dt>
<dd><p id="Par68">ratio of AUC<sub>brain</sub> and AUC<sub>blood</sub></p></dd>
<dt>Bapi</dt>
<dd><p id="Par69">bapineuzumab</p></dd>
<dt>BBB</dt>
<dd><p id="Par70">blood-brain barrier</p></dd>
<dt>CNS</dt>
<dd><p id="Par71">central nervous system</p></dd>
<dt>HRP</dt>
<dd><p id="Par72">horseradish peroxidase</p></dd>
<dt>KiH</dt>
<dd><p id="Par73">knob-into-hole</p></dd>
<dt>MFI</dt>
<dd><p id="Par74">mean fluorescent intensity</p></dd>
<dt>mTfR</dt>
<dd><p id="Par75">mouse transferrin receptor 1</p></dd>
<dt>OD</dt>
<dd><p id="Par76">optical density</p></dd>
<dt>PBS</dt>
<dd><p id="Par77">phosphate buffered saline</p></dd>
<dt>PET</dt>
<dd><p id="Par78">positron emission tomography: TfR: transferrin receptor</p></dd>
<dt>WT</dt>
<dd><p id="Par79">wild-type</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>GB, DS, KGA, and SSy contributed to the study conception and design. GB, LS, KGA and ES performed material preparation. GB, SSi, TD, AD, SLB, DS and SSy performed data collection. GB performed the data analysis and wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript and have read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Open access funding provided by Uppsala University. This project received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813528, the Swedish Research Council (2021 − 01083 and 2021–03524), the Swedish Innovation Agency (2019–00106), Alzheimerfonden, Hjärnfonden, Hedlunds stiftelse, Torsten Söderbergs stiftelse, Åhlenstiftelsen, Stiftelsen för gamla tjänarinnor, Stohnes stiftelse, Magnus Bergvalls stiftelse, and Konung Gustaf V: s och Drottning Victorias frimuarestiftelse. The funding organizations did not take part in designing the study, in collecting, analysing, or interpreting the data, nor in writing the manuscript.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar3"><h3 class="pmc_sec_title">Ethics approval</h3>
<p id="Par57">All animal experiments described in this study were approved by the Uppsala County Animal Ethics board (5.8.18–20401/2020), following the rules and regulations of the Swedish Animal Welfare Agency and complied with the European Communities Council Directive of 22 September 2010 (2010/63/EU).</p></section><section id="FPar1"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par58">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par59">GB, SSi, LS and KGA are employees of BioArctic AB, Sweden. The other authors declare that they have no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Mukherjee AG, Wanjari UR, Gopalakrishnan AV, et al. Evolving strategies and application of proteins and peptide therapeutics in cancer treatment. Biomedicine and Pharmacotherapy. Volume 163. Elsevier Masson s.r.l.; 2023.</cite> [<a href="https://doi.org/10.1016/j.biopha.2023.114832" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37150032/" class="usa-link">PubMed</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Zhou J, Deng H, Xiao H. Research and development of antibody-based novel anti-cancer drugs: an overview. Intelligent Pharmacy. Volume 1. KeAi Publishing Communications Ltd.; 2023.</cite>
</li>
<li id="CR3">
<span class="label">3.</span><cite>Decourt B, Noorda K, Noorda K, Shi J, Sabbagh MN. Review of advanced drug trials focusing on the reduction of brain Beta-Amyloid to prevent and treat dementia. J Exp Pharmacol. 2022;14:331–52.
</cite> [<a href="https://doi.org/10.2147/JEP.S265626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9632331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36339394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Decourt%20B,%20Noorda%20K,%20Noorda%20K,%20Shi%20J,%20Sabbagh%20MN.%20Review%20of%20advanced%20drug%20trials%20focusing%20on%20the%20reduction%20of%20brain%20Beta-Amyloid%20to%20prevent%20and%20treat%20dementia.%20J%20Exp%20Pharmacol.%202022;14:331%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Magnusson K, Sehlin D, Syvänen S, et al. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP Transgenic mouse brain. J Alzheimer’s Disease. 2013;37:29–40.
</cite> [<a href="https://doi.org/10.3233/JAD-130029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23780660/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Magnusson%20K,%20Sehlin%20D,%20Syv%C3%A4nen%20S,%20et%20al.%20Specific%20uptake%20of%20an%20amyloid-%CE%B2%20protofibril-binding%20antibody-tracer%20in%20A%CE%B2PP%20Transgenic%20mouse%20brain.%20J%20Alzheimer%E2%80%99s%20Disease.%202013;37:29%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Hultqvist G, Syvänen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7:308–18.
</cite> [<a href="https://doi.org/10.7150/thno.17155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5197066/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28042336/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hultqvist%20G,%20Syv%C3%A4nen%20S,%20Fang%20XT,%20Lannfelt%20L,%20Sehlin%20D.%20Bivalent%20brain%20shuttle%20increases%20antibody%20uptake%20by%20monovalent%20binding%20to%20the%20transferrin%20receptor.%20Theranostics.%202017;7:308%E2%80%9318." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Syvänen S, Hultqvist G, Gustavsson T, et al. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10:1–10.
</cite> [<a href="https://doi.org/10.1186/s13195-018-0377-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5968497/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29793530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Syv%C3%A4nen%20S,%20Hultqvist%20G,%20Gustavsson%20T,%20et%20al.%20Efficient%20clearance%20of%20A%CE%B2%20protofibrils%20in%20A%CE%B2PP-transgenic%20mice%20treated%20with%20a%20brain-penetrating%20bifunctional%20antibody.%20Alzheimers%20Res%20Ther.%202018;10:1%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Sehlin D, Stocki P, Gustavsson T, et al. Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. FASEB J. 2020;34:13272–83.
</cite> [<a href="https://doi.org/10.1096/fj.202000610RR" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32779267/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sehlin%20D,%20Stocki%20P,%20Gustavsson%20T,%20et%20al.%20Brain%20delivery%20of%20biologics%20using%20a%20cross-species%20reactive%20transferrin%20receptor%201%20VNAR%20shuttle.%20FASEB%20J.%202020;34:13272%E2%80%9383." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A. 1999;96:254–9.
</cite> [<a href="https://doi.org/10.1073/pnas.96.1.254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC15126/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9874805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20D,%20Pardridge%20WM.%20Neuroprotection%20with%20noninvasive%20neurotrophin%20delivery%20to%20the%20brain.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%201999;96:254%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Baringer SL, Simpson IA, Connor JR. Brain iron acquisition: an overview of homeostatic regulation and disease dysregulation. J Neurochem. 2023; 1–18.</cite> [<a href="https://doi.org/10.1111/jnc.15819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37000124/" class="usa-link">PubMed</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Okuyama T, Eto Y, Sakai N et al. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Molecular Therapy [Internet]. 2019; 27: 456–64. Available at: 10.1016/j.ymthe.2018.12.005</cite> [<a href="https://doi.org/10.1016/j.ymthe.2018.12.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6391590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30595526/" class="usa-link">PubMed</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Okuyama T, Eto Y, Sakai N et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Molecular Therapy [Internet]. 2021; 29: 671–9. Available at: 10.1016/j.ymthe.2020.09.039</cite> [<a href="https://doi.org/10.1016/j.ymthe.2020.09.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7854283/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33038326/" class="usa-link">PubMed</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Mullard A. Blood–brain barrier-traversing biologic secures regulatory approval, in Japan. Nat Rev Drug Discovery. 2021; 332.</cite> [<a href="https://doi.org/10.1038/d41573-021-00066-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33850321/" class="usa-link">PubMed</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood–brain barrier. Nat Rev Drug Discov. 2021;20:362–83.
</cite> [<a href="https://doi.org/10.1038/s41573-021-00139-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33649582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Terstappen%20GC,%20Meyer%20AH,%20Bell%20RD,%20Zhang%20W.%20Strategies%20for%20delivering%20therapeutics%20across%20the%20blood%E2%80%93brain%20barrier.%20Nat%20Rev%20Drug%20Discov.%202021;20:362%E2%80%9383." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Schöll M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79:229–36.
</cite> [<a href="https://doi.org/10.1212/WNL.0b013e31825fdf18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22700814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sch%C3%B6ll%20M,%20Wall%20A,%20Thordardottir%20S,%20et%20al.%20Low%20PiB%20PET%20retention%20in%20presence%20of%20pathologic%20CSF%20biomarkers%20in%20Arctic%20APP%20mutation%20carriers.%20Neurology.%202012;79:229%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Sehlin D, Syvänen S. Engineered antibodies: new possibilities for brain PET ? Eur J Nucl Med Mol Imaging. 2019;11:1–11.</cite> [<a href="https://doi.org/10.1007/s00259-019-04426-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6879437/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31342134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sehlin%20D,%20Syv%C3%A4nen%20S.%20Engineered%20antibodies:%20new%20possibilities%20for%20brain%20PET%20?%20Eur%20J%20Nucl%20Med%20Mol%20Imaging.%202019;11:1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Ikonomovic MD, Buckley CJ, Abrahamson EE, et al. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in alzheimer’s disease. Acta Neuropathol. 2020;140:463–76.
</cite> [<a href="https://doi.org/10.1007/s00401-020-02175-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7498488/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32772265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ikonomovic%20MD,%20Buckley%20CJ,%20Abrahamson%20EE,%20et%20al.%20Post-mortem%20analyses%20of%20PiB%20and%20flutemetamol%20in%20diffuse%20and%20cored%20amyloid-%CE%B2%20plaques%20in%20alzheimer%E2%80%99s%20disease.%20Acta%20Neuropathol.%202020;140:463%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S. Antibody-based PET imaging of amyloid beta in mouse models of alzheimer’s disease. Nat Commun. 2016;7:1–11.</cite> [<a href="https://doi.org/10.1038/ncomms10759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4762893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26892305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sehlin%20D,%20Fang%20XT,%20Cato%20L,%20Antoni%20G,%20Lannfelt%20L,%20Syv%C3%A4nen%20S.%20Antibody-based%20PET%20imaging%20of%20amyloid%20beta%20in%20mouse%20models%20of%20alzheimer%E2%80%99s%20disease.%20Nat%20Commun.%202016;7:1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Meier SR, Syvänen S, Hultqvist G, et al. Antibody-based in vivo PET imaging detects amyloid-ß reduction in alzheimer Transgenic mice after BACE-1 Inhibition. J Nucl Med. 2018;59:1885–91.
</cite> [<a href="https://doi.org/10.2967/jnumed.118.213140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6278900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29853653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meier%20SR,%20Syv%C3%A4nen%20S,%20Hultqvist%20G,%20et%20al.%20Antibody-based%20in%20vivo%20PET%20imaging%20detects%20amyloid-%C3%9F%20reduction%20in%20alzheimer%20Transgenic%20mice%20after%20BACE-1%20Inhibition.%20J%20Nucl%20Med.%202018;59:1885%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syvänen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. NeuroImage. 2019;184:881–8.
</cite> [<a href="https://doi.org/10.1016/j.neuroimage.2018.10.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30300753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20XT,%20Hultqvist%20G,%20Meier%20SR,%20Antoni%20G,%20Sehlin%20D,%20Syv%C3%A4nen%20S.%20High%20detection%20sensitivity%20with%20antibody-based%20PET%20radioligand%20for%20amyloid%20beta%20in%20brain.%20NeuroImage.%202019;184:881%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Meier SR, Sehlin D, Roshanbin S et al. 11 C-PIB and 124 I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention. J Nucl Med. 2021; jnumed.121.262083.</cite> [<a href="https://doi.org/10.2967/jnumed.121.262083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8805773/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34088777/" class="usa-link">PubMed</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Bonvicini G, Syvänen S, Andersson KG, Haaparanta-Solin M, López-Picón F, Sehlin D. ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein. Transl Neurodegener [Internet]. 2022; 11: 1–14. Available at: 10.1186/s40035-022-00324-y</cite> [<a href="https://doi.org/10.1186/s40035-022-00324-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9791759/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36567338/" class="usa-link">PubMed</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:1–9.</cite> [<a href="https://doi.org/10.1126/scitranslmed.3002230" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21613623/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20YJ,%20Zhang%20Y,%20Kenrick%20M,%20et%20al.%20Boosting%20brain%20uptake%20of%20a%20therapeutic%20antibody%20by%20reducing%20its%20affinity%20for%20a%20transcytosis%20target.%20Sci%20Transl%20Med.%202011;3:1%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Bien-Ly N, Yu YJ, Bumbaca D, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211:233–44.
</cite> [<a href="https://doi.org/10.1084/jem.20131660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3920563/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24470444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bien-Ly%20N,%20Yu%20YJ,%20Bumbaca%20D,%20et%20al.%20Transferrin%20receptor%20(TfR)%20trafficking%20determines%20brain%20uptake%20of%20TfR%20antibody%20affinity%20variants.%20J%20Exp%20Med.%202014;211:233%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Yu YJ, Atwal JK, Zhang Y, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6:1–11.</cite> [<a href="https://doi.org/10.1126/scitranslmed.3009835" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25378646/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20YJ,%20Atwal%20JK,%20Zhang%20Y,%20et%20al.%20Therapeutic%20bispecific%20antibodies%20cross%20the%20blood-brain%20barrier%20in%20nonhuman%20primates.%20Sci%20Transl%20Med.%202014;6:1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Webster CI, Hatcher J, Burrell M, et al. Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-Transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. Pain. 2017;158:660–8.
</cite> [<a href="https://doi.org/10.1097/j.pain.0000000000000810" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5359788/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28009628/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Webster%20CI,%20Hatcher%20J,%20Burrell%20M,%20et%20al.%20Enhanced%20delivery%20of%20IL-1%20receptor%20antagonist%20to%20the%20central%20nervous%20system%20as%20a%20novel%20anti-Transferrin%20receptor-IL-1RA%20fusion%20reverses%20neuropathic%20mechanical%20hypersensitivity.%20Pain.%202017;158:660%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Haqqani AS, Thom G, Burrell M, et al. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity. J Neurochem. 2018;146:735–52.
</cite> [<a href="https://doi.org/10.1111/jnc.14482" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6175443/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29877588/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haqqani%20AS,%20Thom%20G,%20Burrell%20M,%20et%20al.%20Intracellular%20sorting%20and%20transcytosis%20of%20the%20rat%20transferrin%20receptor%20antibody%20OX26%20across%20the%20blood-brain%20barrier%20in%20vitro%20is%20dependent%20on%20its%20binding%20affinity.%20J%20Neurochem.%202018;146:735%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Thom G, Burrell M, Haqqani AS, et al. Enhanced delivery of Galanin conjugates to the brain through bioengineering of the Anti-Transferrin receptor antibody OX26. Mol Pharm. 2018;15:1420–31.
</cite> [<a href="https://doi.org/10.1021/acs.molpharmaceut.7b00937" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29485883/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thom%20G,%20Burrell%20M,%20Haqqani%20AS,%20et%20al.%20Enhanced%20delivery%20of%20Galanin%20conjugates%20to%20the%20brain%20through%20bioengineering%20of%20the%20Anti-Transferrin%20receptor%20antibody%20OX26.%20Mol%20Pharm.%202018;15:1420%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Faresjö R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syvänen S. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS [Internet]. 2021; 18: 1–15. Available at: 10.1186/s12987-021-00257-0</cite> [<a href="https://doi.org/10.1186/s12987-021-00257-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8170802/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34078410/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Bonvicini G, Singh S, Sandersjöö L, Sehlin D, Syvänen S, Andersson KG. The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo. Fluids Barriers CNS. 2025; 22.</cite> [<a href="https://doi.org/10.1186/s12987-025-00643-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11980351/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40200213/" class="usa-link">PubMed</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49–60.
</cite> [<a href="https://doi.org/10.1016/j.neuron.2013.10.061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24411731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Niewoehner%20J,%20Bohrmann%20B,%20Collin%20L,%20et%20al.%20Increased%20brain%20penetration%20and%20potency%20of%20a%20therapeutic%20antibody%20using%20a%20monovalent%20molecular%20shuttle.%20Neuron.%202014;81:49%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Sade H, Baumgartner C, Hugenmatter A, Moessner E, Freskgård PO, Niewoehner J. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS ONE. 2014;9:e96340.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0096340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4005765/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24788759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sade%20H,%20Baumgartner%20C,%20Hugenmatter%20A,%20Moessner%20E,%20Freskg%C3%A5rd%20PO,%20Niewoehner%20J.%20A%20human%20blood-brain%20barrier%20transcytosis%20assay%20reveals%20antibody%20transcytosis%20influenced%20by%20pH-dependent%20receptor%20binding.%20PLoS%20ONE.%202014;9:e96340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Esparza TJ, Su S, Francescutti CM, Rodionova E, Kim JH, Brody DL. Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody. Fluids Barriers CNS. 2023; 20.</cite> [<a href="https://doi.org/10.1186/s12987-023-00462-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10463325/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37620930/" class="usa-link">PubMed</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292:1048–52.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10688622/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20HJ,%20Engelhardt%20B,%20Lesley%20J,%20Bickel%20U,%20Pardridge%20WM.%20Targeting%20rat%20anti-mouse%20transferrin%20receptor%20monoclonal%20antibodies%20through%20blood-brain%20barrier%20in%20mouse.%20J%20Pharmacol%20Exp%20Ther.%202000;292:1048%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Abushouk AI, Elmaraezy A, Aglan A, et al. Bapineuzumab for mild to moderate alzheimer’s disease: A meta-analysis of randomized controlled trials. BMC Neurol. 2017;17:1–13.
</cite> [<a href="https://doi.org/10.1186/s12883-017-0850-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5381133/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28376794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Abushouk%20AI,%20Elmaraezy%20A,%20Aglan%20A,%20et%20al.%20Bapineuzumab%20for%20mild%20to%20moderate%20alzheimer%E2%80%99s%20disease:%20A%20meta-analysis%20of%20randomized%20controlled%20trials.%20BMC%20Neurol.%202017;17:1%E2%80%9313." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Giese G, Williams A, Rodriguez M, Persson J. Bispecific antibody process development: assembly and purification of knob and hole bispecific antibodies. Biotechnol Prog. 2018;34:397–404.
</cite> [<a href="https://doi.org/10.1002/btpr.2590" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29193902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Giese%20G,%20Williams%20A,%20Rodriguez%20M,%20Persson%20J.%20Bispecific%20antibody%20process%20development:%20assembly%20and%20purification%20of%20knob%20and%20hole%20bispecific%20antibodies.%20Biotechnol%20Prog.%202018;34:397%E2%80%93404." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Merchant AM, Zhu Z, Yuan JQ, et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–81.
</cite> [<a href="https://doi.org/10.1038/nbt0798-677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9661204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Merchant%20AM,%20Zhu%20Z,%20Yuan%20JQ,%20et%20al.%20An%20efficient%20route%20to%20human%20bispecific%20IgG.%20Nat%20Biotechnol.%201998;16:677%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Do TM, Capdevila C, Pradier L et al. Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model. Mol Ther Methods Clin Dev [Internet]. 2020; 19: 58–77. Available at: 10.1016/j.omtm.2020.08.014</cite> [<a href="https://doi.org/10.1016/j.omtm.2020.08.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7502788/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33005703/" class="usa-link">PubMed</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1–20.
</cite> [<a href="https://doi.org/10.3389/fimmu.2019.01296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6568213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31231397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saunders%20KO.%20Conceptual%20approaches%20to%20modulating%20antibody%20effector%20functions%20and%20circulation%20half-life.%20Front%20Immunol.%202019;10:1%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Bonvicini G, Bagawath Singh S, Nygren P et al. Comparing in vitro affinity measurements of antibodies to TfR1: surface plasmon resonance versus on-cell affinity. Anal Biochem. 2024; 686.</cite> [<a href="https://doi.org/10.1016/j.ab.2023.115406" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38006952/" class="usa-link">PubMed</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Greenwood FC, Hunter WM, Glover JS. The Preparation of I-131-Labelled human growth hormone of high specific. Biochem J. 1963;89:114–23.
</cite> [<a href="https://doi.org/10.1042/bj0890114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1202279/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14097352/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Greenwood%20FC,%20Hunter%20WM,%20Glover%20JS.%20The%20Preparation%20of%20I-131-Labelled%20human%20growth%20hormone%20of%20high%20specific.%20Biochem%20J.%201963;89:114%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Saito T, Matsuba Y, Mihira N, et al. Single app knock-in mouse models of alzheimer’s disease. Nat Neurosci. 2014;17:661–3.
</cite> [<a href="https://doi.org/10.1038/nn.3697" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24728269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saito%20T,%20Matsuba%20Y,%20Mihira%20N,%20et%20al.%20Single%20app%20knock-in%20mouse%20models%20of%20alzheimer%E2%80%99s%20disease.%20Nat%20Neurosci.%202014;17:661%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Gustavsson T, Metzendorf NG, Wik E et al. Longterm effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease. Alzheimers Res Ther [Internet]. 2023; 15: 1–16. Available at: 10.1186/s13195-023-01236-3</cite> [<a href="https://doi.org/10.1186/s13195-023-01236-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10152635/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37131196/" class="usa-link">PubMed</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Gustafsson S, Gustavsson T, Roshanbin S, et al. Blood-brain barrier integrity in a mouse model of alzheimer’s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1–9.
</cite> [<a href="https://doi.org/10.1016/j.neuropharm.2018.09.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30201212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gustafsson%20S,%20Gustavsson%20T,%20Roshanbin%20S,%20et%20al.%20Blood-brain%20barrier%20integrity%20in%20a%20mouse%20model%20of%20alzheimer%E2%80%99s%20disease%20with%20or%20without%20acute%203D6%20immunotherapy.%20Neuropharmacology.%202018;143:1%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Loening AM, Gambhir SS. AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–7.
</cite> [<a href="https://doi.org/10.1162/15353500200303133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14649056/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Loening%20AM,%20Gambhir%20SS.%20AMIDE:%20A%20free%20software%20tool%20for%20multimodality%20medical%20image%20analysis.%20Mol%20Imaging.%202003;2:131%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Ma Y, Hof PR, Grant SC, et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience. 2005;135:1203–15.
</cite> [<a href="https://doi.org/10.1016/j.neuroscience.2005.07.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16165303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20Y,%20Hof%20PR,%20Grant%20SC,%20et%20al.%20A%20three-dimensional%20digital%20atlas%20database%20of%20the%20adult%20C57BL/6J%20mouse%20brain%20by%20magnetic%20resonance%20microscopy.%20Neuroscience.%202005;135:1203%E2%80%9315." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Wuensche TE, Stergiou N, Mes I, et al. Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody – The choice of chelator is essential. Theranostics. 2022;12:7067–79.
</cite> [<a href="https://doi.org/10.7150/thno.73509" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9576608/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36276653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wuensche%20TE,%20Stergiou%20N,%20Mes%20I,%20et%20al.%20Advancing%2089Zr-immuno-PET%20in%20neuroscience%20with%20a%20bispecific%20anti-amyloid-beta%20monoclonal%20antibody%20%E2%80%93%20The%20choice%20of%20chelator%20is%20essential.%20Theranostics.%202022;12:7067%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Shojaei M, Schaefer R, Schlepckow K, et al. PET imaging of microglia in alzheimer’s disease using copper-64 labeled TREM2 antibodies. Theranostics. 2024;14:6319–36.
</cite> [<a href="https://doi.org/10.7150/thno.97149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11488106/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39431020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shojaei%20M,%20Schaefer%20R,%20Schlepckow%20K,%20et%20al.%20PET%20imaging%20of%20microglia%20in%20alzheimer%E2%80%99s%20disease%20using%20copper-64%20labeled%20TREM2%20antibodies.%20Theranostics.%202024;14:6319%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Roshanbin S, Xiong M, Hultqvist G, et al. Neuropharmacology in vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:1–10.</cite> [<a href="https://doi.org/10.1016/j.neuropharm.2022.108985" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35149134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roshanbin%20S,%20Xiong%20M,%20Hultqvist%20G,%20et%20al.%20Neuropharmacology%20in%20vivo%20imaging%20of%20alpha-synuclein%20with%20antibody-based%20PET.%20Neuropharmacology.%202022;208:1%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Dahlén AD, Roshanbin S, Aguilar X et al. PET imaging of TREM2 in amyloid-beta induced neuroinflammation. Eur J Nucl Med Mol Imaging. 2025.</cite> [<a href="https://doi.org/10.1007/s00259-025-07358-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40434494/" class="usa-link">PubMed</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Gustavsson T, Syvänen S, O’Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of alzheimer’s disease. Transl Neurodegener. 2020;9:1–11.
</cite> [<a href="https://doi.org/10.1186/s40035-020-00214-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7504681/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32951598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gustavsson%20T,%20Syv%C3%A4nen%20S,%20O%E2%80%99Callaghan%20P,%20Sehlin%20D.%20SPECT%20imaging%20of%20distribution%20and%20retention%20of%20a%20brain-penetrating%20bispecific%20amyloid-%CE%B2%20antibody%20in%20a%20mouse%20model%20of%20alzheimer%E2%80%99s%20disease.%20Transl%20Neurodegener.%202020;9:1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Faresjö R, Sjöström EO, Dallas T, et al. Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood-brain barrier and interacts with amyloid β. MAbs. 2024;16:2410968.
</cite> [<a href="https://doi.org/10.1080/19420862.2024.2410968" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11451328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39358860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Faresj%C3%B6%20R,%20Sj%C3%B6str%C3%B6m%20EO,%20Dallas%20T,%20et%20al.%20Single%20domain%20antibody-scFv%20conjugate%20targeting%20amyloid%20%CE%B2%20and%20TfR%20penetrates%20the%20blood-brain%20barrier%20and%20interacts%20with%20amyloid%20%CE%B2.%20MAbs.%202024;16:2410968." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Villaseñor R, Schilling M, Sundaresan J, Lutz Y, Collin L. Sorting tubules regulate Blood-Brain barrier transcytosis. Cell Rep. 2017;21:3256–70.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2017.11.055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29241551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Villase%C3%B1or%20R,%20Schilling%20M,%20Sundaresan%20J,%20Lutz%20Y,%20Collin%20L.%20Sorting%20tubules%20regulate%20Blood-Brain%20barrier%20transcytosis.%20Cell%20Rep.%202017;21:3256%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Veire JL, Lucas MJ, Bond LG, Tripu DR, Tessier PM, Greineder CF. Comparative Radiotracing quantifies brain cellular uptake and catabolism of bispecific antibodies targeting transferrin receptor and CD98hc. ACS Chem Neurosci. 2025.</cite> [<a href="https://doi.org/10.1021/acschemneuro.4c00552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40071777/" class="usa-link">PubMed</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>van den Lopes S, Bratteby K, Aguilar X, Tran TA, Syvänen S, Sehlin D. Radionuclide selection influences imaging outcomes in immunoPET with a brain-penetrant anti-Aβ antibody [Internet]. 2025 Jun. Available at: <a href="http://biorxiv.org/lookup/doi/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://biorxiv.org/lookup/doi/</a>10.1101/2025.05.31.657140</cite>
</li>
<li id="CR55">
<span class="label">55.</span><cite>Cuypers ML, Jaspers T, Clerckx J, et al. Increasing brain half-life of antibodies by additional binding to Myelin oligodendrocyte glycoprotein, a CNS specific protein. Fluids Barriers CNS. 2025;22:11.
</cite> [<a href="https://doi.org/10.1186/s12987-025-00624-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11783731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39885527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cuypers%20ML,%20Jaspers%20T,%20Clerckx%20J,%20et%20al.%20Increasing%20brain%20half-life%20of%20antibodies%20by%20additional%20binding%20to%20Myelin%20oligodendrocyte%20glycoprotein,%20a%20CNS%20specific%20protein.%20Fluids%20Barriers%20CNS.%202025;22:11." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369151/bin/12987_2025_693_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (1.3MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Fluids and Barriers of the CNS are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12987-025-00693-2"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12987_2025_Article_693.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12369151/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12369151/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369151%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369151/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12369151/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12369151/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40842024/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12369151/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40842024/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12369151/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12369151/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="cYqlSigsCmk3ycFSgfnk69JEj4q2JnwMIevvmP6tWca0ZnepcacOmDlV6ziE6iqV">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
